R
Richard E. Royal
Researcher at University of Texas MD Anderson Cancer Center
Publications - 115
Citations - 18202
Richard E. Royal is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Cancer & Antigen. The author has an hindex of 44, co-authored 113 publications receiving 16457 citations. Previous affiliations of Richard E. Royal include University of Texas at Austin & National Institutes of Health.
Papers
More filters
Journal ArticleDOI
Cancer regression in patients after transfer of genetically engineered lymphocytes
Richard A. Morgan,Mark E. Dudley,John R. Wunderlich,Michael S. Hughes,James Chih-Hsin Yang,Richard M. Sherry,Richard E. Royal,Suzanne L. Topalian,Udai S. Kammula,Nicholas P. Restifo,Zhili Zheng,Azam V. Nahvi,Christiaan R. de Vries,Linda Rogers-Freezer,Sharon Mavroukakis,Steven A. Rosenberg +15 more
TL;DR: The ability to specifically confer tumor recognition by autologous lymphocytes from peripheral blood by using a retrovirus that encodes a T cell receptor is reported.
Journal ArticleDOI
Adoptive Cell Transfer Therapy Following Non-Myeloablative but Lymphodepleting Chemotherapy for the Treatment of Patients With Refractory Metastatic Melanoma
Mark E. Dudley,John R. Wunderlich,James Chih-Hsin Yang,Richard M. Sherry,Suzanne L. Topalian,Nicholas P. Restifo,Richard E. Royal,Udai S. Kammula,Donald E. White,Sharon Mavroukakis,Linda J. Rogers,Gerald J. Gracia,Stephanie Jones,David P. Mangiameli,Michelle M. Pelletier,Juan Gea-Banacloche,Michael R. Robinson,David Berman,Armando C. Filie,Andrea Abati,Steven A. Rosenberg +20 more
TL;DR: Lymphodepleting chemotherapy followed by the transfer of highly avid antitumor lymphocytes can mediate significant tumor regression in heavily pretreated patients with IL-2 refractory metastatic melanoma.
Journal ArticleDOI
Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen.
Laura A. Johnson,Richard A. Morgan,Mark E. Dudley,Lydie Cassard,James Chih-Hsin Yang,Michael S. Hughes,Udai S. Kammula,Richard E. Royal,Richard M. Sherry,John R. Wunderlich,Chyi-Chia Richard Lee,Nicholas P. Restifo,Susan L. Schwarz,Alexandria P. Cogdill,Rachel Bishop,Hung Kim,Carmen C. Brewer,Susan F. Rudy,Carter VanWaes,Jeremy L. Davis,Aarti Mathur,Robert T. Ripley,Debbie Ann N. Nathan,Carolyn M. Laurencot,Steven A. Rosenberg +24 more
TL;DR: T cells expressing highly reactive TCRs mediate cancer regression in humans and target rare cognate-antigen-containing cells throughout the body, a finding with important implications for the gene therapy of cancer.
Journal ArticleDOI
Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens
Mark E. Dudley,James Chih-Hsin Yang,Richard M. Sherry,Michael S. Hughes,Richard E. Royal,Udai S. Kammula,Paul F. Robbins,Jian Ping Huang,Deborah Citrin,Susan F. Leitman,John R. Wunderlich,Nicholas P. Restifo,Armen A. Thomasian,Stephanie G. Downey,Franz O. Smith,Jacob A. Klapper,Kathleen E. Morton,Carolyn M. Laurencot,Donald E. White,Steven A. Rosenberg +19 more
TL;DR: Host lymphodepletion followed by autologous TIL transfer and IL-2 results in objective response rates of 50% to 70% in patients with metastatic melanoma refractory to standard therapies.
Journal ArticleDOI
Autoimmunity Correlates With Tumor Regression in Patients With Metastatic Melanoma Treated With Anti–Cytotoxic T-Lymphocyte Antigen-4
Peter Attia,Giao Q. Phan,Ajay V. Maker,Michael R. Robinson,Martha Quezado,James Chih-Hsin Yang,Richard M. Sherry,Suzanne L. Topalian,Udai S. Kammula,Richard E. Royal,Nicholas P. Restifo,Leah R. Haworth,Catherine Levy,Sharon Mavroukakis,Geoff M. Nichol,Michael Yellin,Steven A. Rosenberg +16 more
TL;DR: Administration of anti-CTLA-4 monoclonal antibody plus peptide vaccination can cause durable objective responses, which correlate with the induction of autoimmunity, in patients with metastatic melanoma.